Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound (ELF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02044523|
Recruitment Status : Recruiting
First Posted : January 24, 2014
Last Update Posted : August 3, 2017
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis. The traditional diagnostic approach requires a biopsy for assessing the severity of liver disease prior to therapy.
However, liver biopsy has several limitations: cost, sampling error, and procedure-related morbidity and mortality. Considering the high prevalence of viral hepatitis and nonalcoholic fatty liver disease, a condition often associated with obesity and type 2 diabetes, there is an urgent need for noninvasive screening, diagnosis and monitoring strategies of chronic liver disease severity.
Our team has the expertise to investigate ultrasound-based and magnetic resonance-based elastographic methods for the noninvasive staging of liver fibrosis.
The primary objective of this cross-sectional study is to compare the sensitivity of elastographic methods for detecting histology-determined significant fibrosis.
The secondary objectives are to compare the diagnostic accuracy of these elastographic methods and the influence of potential confounders (inflammation, steatosis and iron deposition) on their diagnostic accuracy.
|Condition or disease||Intervention/treatment|
|Hepatitis C Hepatitis B Nonalcoholic Fatty Liver Disease (NAFLD) Nonalcoholic Steatohepatitis (NASH)||Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|
Background: Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to cirrhosis (the end stage) and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis. The amount of fibrosis determines the prognosis and influences the response to treatment of chronic liver disease.
Several elastographic methods have been proposed for noninvasive detection and staging of liver fibrosis. Transient elastography (Fibroscan) is widely used by clinicians. Acoustic radiation force impulse (ARFI) is an elastography technique recently integrated in clinical ultrasound systems that may provide similar diagnostic performance to transient elastography. Magnetic resonance elastography (MRE) is a new method that can be integrated to a liver MRI study, which would allow liver stiffness, steatosis, iron overload and inflammation quantification in chronic liver disease.
Objectives: 1) To compare the sensitivity of MRE and ARFI for detecting histology-determined significant fibrosis (F ≥ 2). Secondary objectives: 2) To compare the diagnostic accuracy of MRE, ARFI and Fibroscan for predicting histology-determined fibrosis stages. 3) To determine the influence of inflammation, steatosis, and iron deposition on the diagnostic accuracy of MRE, ARFI and Fibroscan for predicting fibrosis. 4) To determine thresholds optimizing sensitivity of ARFI and Fibroscan to screen patients and optimizing specificity of MRE to confirm liver fibrosis stage.
Design: This will be a cross-sectional imaging trial comparing feasibility, diagnostic and fibrosis staging accuracy of stiffness measurements by elastographic methods in 108 patients with chronic liver disease, using histopathology as the reference standard. Paired index tests (MRE, ARFI and Fibroscan) will be performed as research procedures in close temporal proximity to the reference test (liver biopsy).
Inclusion criteria: consecutive adult patients with known or suspected chronic liver disease secondary to hepatitis B virus, hepatitis C virus, or nonalcoholic fatty liver disease (NAFLD) undergoing a liver biopsy for clinical indications.
Exclusion criteria: any contraindication to MRI, refusal to participate or provide informed consent, pregnant women, any other cause of chronic liver disease than hepatitis B, hepatitis C or NAFLD.
|Study Type :||Observational|
|Estimated Enrollment :||108 participants|
|Official Title:||Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
Hepatis C, Hepatitis B, NAFLD
All patients enrolled will undergo:
Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
- Histology-determined fibrosis stage [ Time Frame: Within 6 weeks of elastographic methods ]
- Fibroscan-determined liver stiffness [ Time Frame: Within 6 weeks of liver biopsy ]
- Acoustic Radiation Force Impulse (ARFI)-determined liver stiffness [ Time Frame: Within 6 weeks of liver biopsy ]
- Magnetic Resonance Elastography (MRE)-determined liver stiffness [ Time Frame: Within 6 weeks of liver biopsy ]
- Magnetic Resonance Imaging (MRI)-based Proton Density Fat Fraction (PDFF) [ Time Frame: Within 6 weeks of liver biopsy ]
- Magnetic Resonance Imaging (MRI) cine-tagging of cardiac-induced motion for staging liver fibrosis [ Time Frame: Within 6 weeks of liver biopsy ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02044523
|Contact: An Tang, MD, MSc||514-890-8000 ext firstname.lastname@example.org|
|Contact: Assia Belblidia||514-890-8000 ext email@example.com|
|Centre Hospitalier de l'Université de Montréal||Recruiting|
|Montreal, Quebec, Canada, H2X 0A9|
|Contact: An Tang, MD, MSc 514-890-8000 ext 36400 firstname.lastname@example.org|
|Sub-Investigator: Damien Olivié, MD|
|Sub-Investigator: Claire Wartelle-Bladou, MD|
|Sub-Investigator: Guy Cloutier, PhD, Ing.|
|Sub-Investigator: Jacques De Guise, PhD, ing.|
|Sub-Investigator: Louis Gaboury, MD|
|Sub-Investigator: Guillaume Gilbert, PhD|
|Sub-Investigator: Claude Kauffmann, PhD, ing.|
|Sub-Investigator: Gilles Soulez, MD, Msc|
|Principal Investigator:||An Tang, MD, MSc||Centre hospitalier de l'Université de Montréal (CHUM)|